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Carboxypeptidase-M is regulated by lipids and CSFs
in macrophages and dendritic cells and expressed
selectively in tissue granulomas and foam cells
Ioannis Tsakiris1,2, Daniel Torocsik3,4, Adrienn Gyongyosi3, Aniko Dozsa3, Istvan Szatmari3, Attila Szanto3,
Gyorgyike Soos1, Zoltan Nemes1, Laszlo Igali5, Ildiko Marton2, Zoltan Takats6, Laszlo Nagy3 and Balazs Dezso1,2,4
Granulomatous inflammations, characterized by the presence of activated macrophages (MAs) forming epithelioid cell
(EPC) clusters, are usually easy to recognize. However, in ambiguous cases the use of a MA marker that expresses
selectively in EPCs may be needed. Here, we report that carboxypeptidase-M (CPM), a MA-differentiation marker, is
preferentially induced in EPCs of all granuloma types studied, but not in resting MAs. As CPM is not expressed con-
stitutively in MAs, this allows utilization of CPM-immunohistochemistry in diagnostics of minute granuloma detection
when dense non-granulomatous MAs are also present. Despite this rule, hardly any detectable CPM was found in
advanced/active tubercle caseous disease, albeit in early tuberculosis granuloma, MAs still expressed CPM. Indeed, in vitro
both the CPM-protein and -mRNA became downregulated when MAs were infected with live mycobacteria. In vitro,
MA-CPM transcript is neither induced remarkably by interferon-g, known to cause classical MA activation, nor by IL-4, an
alternative MA activator. Instead, CPM is selectively expressed in lipid-laden MAs, including the foam cells of athero-
sclerotic plaques, xanthomatous lesions and lipid pneumonias. By using serum, rich in lipids, and low-density lipoprotein
(LDL) or VLDL, CPM upregulation could be reproduced in vitro in monocyte-derived MAs both at transcriptional and
protein levels, and the increase is repressed under lipid-depleted conditions. The microarray analyses support the notion
that CPM induction correlates with a robust progressive increase in CPM gene expression during monocyte to MA
maturation and dendritic cell (DC) differentiation mediated by granulocyte–MA-colony-stimulating factorþ IL-4. M-CSF
alone also induced CPM. These results collectively indicate that CPM upregulation in MAs is preferentially associated with
increased lipid uptake, and exposure to CSF, features of EPCs, also. Therefore, CPM-immunohistochemistry is useful for
granuloma and foam MA detections in tissue sections. Furthermore, the present data offer CPM for the first time to be a
novel marker and cellular player in lipid uptake and/or metabolism of MAs by promoting foam cell formation.
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Many intracellular pathogens, persistent or non-degradable
particles or antigens may induce helper T-cell-mediated
delayed-type hypersensitivity reaction resulting in granuloma
formation, a distinct pattern of chronic inflammation.1 The
morphological diagnostic hallmark of such lesions is the
presence of epithelioid cell (EPC) aggregates surrounded
by T-lymphocytes. The EPCs correspond to monocyte (Mo)-
derived tissue macrophages (MA) that became activated
by interferon-g (INFg) of TH1 cells and other cytokines to
undergo morphological transformation into epithelium-like
cell clusters while increasing their phagocytic and antigen-
presenting capacities.2–4 Among the lesional cells, multi-
nucleate cells may also be seen. Granulomatous inflammation
is encountered in special infectious diseases, including
tuberculosis, leprosy, brucellosis, toxoplasmosis and cat-
scratch disease. On the other hand, several immune-mediated
non-infective granulomatous lesions exist that are induced by
unknown or well-defined antigens, as seen in Crohn’s disease,
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sarcoidosis, primary biliary cirrhosis and in lesions associated
with autoimmune conditions, hypersensitive lung and skin
diseases. In addition, non-immune-mediated reactions in
amyloidosis, lipid accumulation and the presence of foreign
particles may also induce granuloma formation. Owing to its
ramifying nature, the recognition of the granulomatous
pattern of an inflammation in a surgical specimen and the
underlying condition is crucial because of the different
disease progressions and clinical outcomes, and the treat-
ment protocols may substantially differ from each other.
Some of the morphological patterns can easily be recognized
using hematoxylin–eosin (H–E), suggestive of the etiology.
However, the diagnosis of the granulomatous nature of
an inflammation in certain conditions may be difficult on
morphological grounds. In some biopsies, only few MAs
in clusters are recognized that may suggest a minute granu-
loma, but the simultaneous presence of nonspecific infla-
mmation, rich in MAs, may obscure the diagnosis. The
granuloma may be verified with the use of combined
immunohistochemistry (IHC) markers for T cells and MAs.
However, they do not provide per se a specific proof for
the presence of a granulomatous process, as leukocytes in
association with nonspecific inflammations may show similar
expression patterns for these IHC markers. To our knowl-
edge, there is presently no antibody in use that could
recognize EPCs distinctly on paraffin sections to identify
granulomas, selectively.
Based on preliminary IHC staining of paraffin sections,5
we found earlier that carboxypeptidase-M (CPM) could be a
candidate marker for a selective detection of EPCs to dif-
ferentiate them from other MA types present in non-granu-
lomatous lesions.5
CPM belongs to the ‘regulatory’ carboxypeptidase (CP)-N/
E subfamily of zinc-dependent enzymes that includes the
adipocyte enhancer-binding protein 1 (AEBP1) located in
the nuclei of MAs.6–9 CPM is a cell membrane-bound pep-
tidase with neutral pH optimum, which metabolizes bio-
active peptides, hormones, cytokines and has been found
in different cell types, including trophoblasts and alveolar
epithelia.10,11 Earlier we demonstrated that a portion of lung
adenocarcinomas produce CPM, mainly in association with
epidermal growth factor recetor (EGFR), and the co-
expression resulted in a poor clinical outcome.12 CPM is
structurally, catalytically and immunologically distinct from
other carboxypeptidases, and expressed on cell membranes
in a glycosyl-phosphatidylinositol-anchored form.13 CPM
hydrolyses the C-terminal basic arginine or lysine of various
peptides, including bradykinin,14 anaphylatoxins and the
EGF to inactivate them or provide an activating ligand
processing for a specific binding to the receptors.6,7,15 Pre-
viously, CPM has been demonstrated in the MA that is
upregulated during Mo–MA differentiation under in vitro
conditions.16–18 However, CPM has not been systematically
analyzed so far in human tissue MAs by means of IHC in a
large variety of inflammatory conditions.
This study evaluates the differential expression pattern
of CPM in various forms of MAs focusing on EPCs of
granulomatous inflammations. Here we demonstrate that
CPM is preferentially expressed in EPCs of virtually any type
of granulomata, and in lipid-containing tissue MAs, includ-
ing the foam cells of atherosclerotic plaques and xanthoma-
tous lesions, while other MA types remained negative.
Supporting the IHC findings, the in vitro experiments using
quantitative real-time RT-PCR (qRT-PCR) and the micro-
array analyses revealed that the observed acute CPM-mRNA
and -protein upregulations correlated with a robust CPM
gene activation induced by serum lipids in differentia-
ting MAs or granulocyte–MA-colony-stimulating factor
(GM-CSF)þ IL-4 in developing dendritic cells (DCs). As
EPCs harbor cytoplasmic lipids within a CSF-rich environ-
ment,19–26 these may explain our finding that CPM-IHC is
highly reproducible for the identification of EPC-type MA
subpopulations. Therefore, CPM can be nominated as a reli-
able granuloma and foam cell marker for routine diagnostic
purposes.
MATERIALS AND METHODS
Formalin-fixed paraffin-embedded human tissues were
obtained from the archives of the Department of Patho-
logy, University of Debrecen, utilizing protocols approved
by the respective institutional review boards. The samples
included in this study were all surgical specimens with
various forms of inflammations obtained from 246 anonym
cases (Supplementary Table S1 and Supplementary Infor-
mation).
IHC and Immunofluorescent Stainings
Immune-stainings for CPM were performed on antigen-
retrieved paraffin sections using monoclonal antibody (mAB)
to CPM ( 1/25; Novocastra, Newcastle, UK; clone 1C2-
IgG1), followed by an EnVisionþ -HRP detection (Dako,
Glostrup, Denmark) with VIP (purple) or DAB (brown)
peroxidase substrates (Vector Labs, Peterborough, UK) as
described recently in detail.5,12,27 Alternatively, an automated
immune-stainer was used (Bond, Leica). For reference, mABs
to CD68 (Dako), CD163 (Novocastra) were used with the
same method. Immunofluorescent (IF) stainings were made
on serial sections of pelleted cells obtained from in vitro
experiments, followed by formalin fixation, paraffin embed-
ding. After 1-h incubation with mAB to CPM, we applied
anti-mouse IgG(Fab)2 coupled to polymer-HRP (Dako), and
tyramide-TMR (tetramethyl-rhodamine; TSA-TMR System;
Perklin-Elmer, USA) as the final (red) fluorochrome.28,29
Nuclear counterstaining was made with DAPI (blue fluores-
cence; Vector Labs). To check the specificity, positive and
negative controls were included as published earlier.12 IHC
for peroxisome proliferator-activated receptor-g (PPARg) was
carried out on pelleted cells using CSAII detection kit (Dako)
as described earlier.28,29
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Laser-Capture Microdissection Isolation of EPCs from
Granuloma Tissues
Cryosections of native lymph nodes harboring sarcoidosis
were stained with RNAse-free H–E to visualize and locate the
epithelioid MA clusters of granulomata. Using serial sections,
these were then in situ laser-microdissected and collected
from the surrounding cells and tissue compartments (Figure
3a1 and a2) using a computer-guided laser-capture micro-
dissection (LCM) microscope (MMI-Olympus LCM system,
Glattbrugg, Switzerland). Cellular RNA was then isolated
with the use of ‘Absolutely Nanoprep RNA’ isolation kit
(Stratagene) according to the vendor’s protocol. The CPM-
mRNA transcript in EPCs, normalized to cyclophilin-A, was
then determined in parallel with reference MA and DC
markers (CD86, MCR1, PPARg) as described earlier.30–32
Monocyte (Mo) Separation
Human Mo from platelet-free buffy coats were isolated from
healthy donors by Ficoll-Hypaque (Pharmacia, Uppsala,
Sweden) gradient-centrifugation and immunomagnetic
cell separation using anti-CD14-conjugated microbeads
(VarioMACS; Miltenyi Biotec, Cologne, Germany) according
to the manufacturer’s protocols and as described earlier.32,33
Cell viability was at least 98%, and Mo purity varied between
95 and 98%. Separated cells were resuspended (1.5 106/ml)
in RPMI-1640 supplemented with 10% heat-inactivated fetal
bovine serum (FBS; Invitrogen, Carlsbad, CA, USA) and
differentiated into MAs in standard conditions at 37 1C
(Supplementary Information and refs. 32, 33). In separate
experiments (n¼ 3), reduced FBS or charcoal-stripped serum
(CCSS; Sigma) were used for lipid depletion, or supple-
mented with 20 mg/ml low-density lipoprotein (LDL) in place
of 10% FBS.
Activation of MAs and Early DC Differentiation
Mo-derived MAs were cultured and differentiated in the
presence of the following activating agents added to Mos at
the 0 time point (0p) of cultivation: LDL, oxLDL, VLDL
(20 mg/ml; Intracel), and 500U/ml GM-CSF or M-CSF, and
for the induction of classical and alternative activation
pathways: 500U/ml interferon-g (IFNg) or IL-4 (all from
Peprotech, London, UK) were added, respectively. Alter-
natively, MAs were loaded with live (L) or heat-killed (HK)
Mycobacterium bovis- bacillus Calmette–Gue´rin tuberculosis
bacilli (TB) (Statens Serum Institut, Copenhagen, Denmark;
cell/TB ratio: 1:1) as published earlier34 and described in
Supplementary Information. HK bacteria were prepared by
incubation for 20min at 95 1C.
For DC differentiation, following early Mo–MA maturation
for 12 h, the cells were cultured with 500U/ml IL-4þ 800U/ml
GM-CSF (Peprotech) for 120 h as described,35,36 or the cyto-
kine cocktail was supplemented with TGF-b (Peprotech) in
various concentrations. Alternatively, DCs were treated with
rosiglitazone (RSG; Alexis Biochemicals) as published pre-
viously.36 At the indicated time points, cells were collected for
paraffin embedding and IF staining,12,28,29 or for qRT-PCR.
Alternatively, the cultured cell monolayers were stained
with Oil-Red-O using standard methods. For combination
of the lipid staining with IHC, following CPM-IF staining
using FITC fluorochrome, monolayers were treated with
50 ng/ml Nile-red35 (Sigma), washed and counterstained
with DAPI.
For FACS analyses, cell stainings were performed using
FITC- or PE-conjugated mABs as described earlier.28 Labeled
ABs for flow cytometry included anti-CD11c-FITC, CD14-
PE, MHC II-PE and isotype-matched controls (BD Phar-
mingen, San Diego, CA, USA). The cells were assessed for
fluorescence intensity using FACS Calibur cytometer (BD
Biosciences). Data analysis was performed using the Cellquest
software (BD Biosciences).
Sampling and RNA Isolation
To obtain total RNA, cells were pelleted at the indicated time
points. RNA was isolated with TRIZOL reagent (Invitrogen)
according to the manufacturer’s protocol. The amount and
quality of total RNA was determined by capillary electro-
phoresis analysis,30 using an Agilent 2100 Bioanalyzer
(Agilent, Technologies, Santa Clara, CA, USA).
qRT-PCR
Samples containing equal amounts of RNA (1 mg) were used
for qRT-PCR.36 cDNA syntheses were performed at 42 1C for
120min and 72 1C for 5min using Superscript II reverse
transcriptase and Random Primers (Invitrogen) according to
the manufacturer’s recommendations. The cDNA obtained
was used for real-time quantitative PCR (ABI PRISM 7900;
Applied Biosystems), 40 cycles of 95 1C for 10 s and 60 1C for
1min. All PCR reactions were carried out in triplicate with
control reactions containing no reverse transcription enzyme.
The sequence of the primers and probes used are as follows:
CPM (550þ ) GTCCTCTCTGCAAACCTCCAT, (624)
CCCAGTTGCTTGAACACCAT, (573þ ) FAM-TGGTGCCC
TCGTGGCCAGTT; cyclophilin (52þ ) ACGGCGAGC
CCTTGG, (117) TTTCTGCTGTCTTTGGGACCT, (69þ )
FAM-CGCGTCTCCTTTGAGCTGTTTGCA; and PPARg
(1313þ ) GATGACAGCGACTTGGCAA, (1379) CTTCAA
TGGGCTTCACATTCA and (1322) FAM-CAAACCTG
GGCGGTCTCCACTGAG. Predesigned assays for human
CD86 (assay ID: Hs01567025_m1) and human MRC1 (assay
ID: Hs00267207_m1), both from Applied Biosystems, were
used. The comparative cycle threshold (Ct) method was
used to quantify transcripts and normalize to cyclophilin-A
expression.36
Microarray Analysis
RNA isolation and the labeling were performed as published
in detail earlier.29,33,37 Briefly, total RNA was isolated as
described above and further purified by using the RNeasy
total RNA isolation kit (Qiagen). cRNA was generated
from 5 mg of total RNA using the SuperScript Choice kit
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Figure 1 Carboxypeptidase-M (CPM) is selectively expressed in epithelioid cells (EPCs) of common lung granulomatous diseases. Identical microscopic
fields of granulomatous lung lesions are shown for comparative macrophage-labeling patterns with the use of anti-CPM (right panel) and common
macrophage-immunohistochemistry (MA-IHC) reference markers (middle). The disease types are indicated on the hematoxylin–eosin (H–E)-stained
photographs (left). (a) The EPCs of sarcoidosis are distinctly labeled with CPM, including the multinucleate cell (arrow). The staining pattern is similar
with CD68, although the latter decorates additional non-granulomatous macrophages (arrowheads). (b) Granuloma (arrows) obtained from early
active tuberculosis shows CPM expression, including the multinucleate macrophages (encircled) and the labeling is restricted to EPCs, as opposed to
pan-macrophage marker CD163, which stains other macrophages as well (middle panel, arrowheads and lower-right), (c) In contrast, palisade
epithelioid cells of advanced tuberculosis, which are labeled intensively with CD68, are basically negative for CPM. Note that some of the multinucleate
cells, however, still express CPM (slim arrows), but others are nearly non-reactive (thick arrows). IHC stainings for a were visualized with VIP (purple),
and for b and c with diaminobenzidine (DAB) (brown) peroxidase chromogenic substrates, respectively. Nuclear counterstains are methyl green or
hematoxylin.
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(Invitrogen) and the High Yield RNA transcript labeling kit
(Enzo Diagnostics). Fragmented cRNA was hybridized to
Affymetrix (Santa Clara, CA, USA) arrays (HU133 Plus 2.0)
according to Affymetrix standard protocols. Analysis was
performed using the GeneSpring7.2 (Agilent Technologies)
software.
Figure 2 Granuloma macrophages invariably express carboxypeptidase-M (CPM) in uncommon lung disorders. (a) In allergic granulomatous alveolitis,
the lesional cells (between thick arrows) are labeled more distinctly with CPM than CD163. As shown the same microscopic field (indicated by the
same alveolus: a), CD163 decorates non-epithelioid reactive macrophages, also (slim arrows) which are negative for CPM. (b) Identical microscopic
field of pulmonary cryptococcosis shows CPM positivity mainly in epithelioid cells (EPCs), as opposed to CD68, which decorates many more macrophages
(arrowheads). Inset demonstrates the PAS-positive cryptococci with high magnification. (c) Wegener granulomatosis (vasculitis): as compared to
the identical necrotizing inflamed vessels (indicated by the thick and slim arrows) and other compartments on serial sections, there is more
prominent CPM staining in macrophages, mainly at sites of tissue damage (the fine cellular detail of the same image in higher magnification is
seen in Supplementary Figure S2).
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Statistical Analysis
Methods for statistical analyses of qRT-PCR are described in
Supplementary Information.
RESULTS
Positive CPM Expressions in Tissues Exhibiting
Granulomatous Inflammations
We examined tissue sections with inflammatory MAs ob-
tained from over 240 cases to check the presence of CPM
(Supplementary Table S1). Resting MAs of normal tissues
and MAs in inflammations with no significant tissue damage
show no or low levels for CPM staining (Supplementary
Figure S1). However, EPCs of all cases with sarcoidosis
(n¼ 48; Figure 1a), early active tuberculosis (n¼ 4; Figure
1b), other pulmonary granulomatosis including Wegener
vasculitis (Figure 2a–c and Supplementary Figure S2), and
cat-scratch disease, toxoplasmosis and tumor-associated
epithelioid lymphadenitis (Figure 3a–d) constantly expressed
CPM, mainly in membrane-bound form. The CPM expres-
sion levels, however, decreased remarkably in palisade epi-
thelioid MAs that are related to advanced caseous-necrotic
granulomas of active tuberculosis (Figure 1c). This appears to
be a tuberculosis-specific phenomenon because other granu-
loma types with necrosis, for example, cat-scratch disease
(Figure 3b) and granulomatous panniculitis (Figure 4c), do
exhibit palisading EPCs, but with CPM expression. On the
other hand, the staining was found not only in mononuclear
EPCs but also in multinucleated MAs (Figure 1a and b).
Based on qRT-PCR analyses, the laser-microdissected EPCs
of sarcoidosis granuloma tissues (n¼ 3) exhibited high CPM-
mRNA transcript levels, as compared to reference MA and
DC markers (MRC1, CD86, PPARg), suggesting active CPM
synthesis with increased protein expression (Figure 3a1–a3).
Furthermore, CPM expression was seen in non-immune
granulomas, including granulomatous amyloidosis (amyloi-
doma) and foreign body giant-cell reactions (Figure 4a
and b). When minute granulomata are present admixed with
other inflammatory (non-granulomatous) MAs, as seen in
certain cases of Crohn’s disease, CPM reliably ‘picks up’ the
lesional EPCs from tissues to allow establishing adequate
diagnosis (Figure 4d, right pictures). In addition, we found
CPM-positive MAs in subcutaneous gouty tophus and
rheumatoid nodules with various expression levels (not
shown). According to the comparative immune-staining
using common reference MA markers, anti-CPM appears to
label EPCs selectively from the rest of other MAs that were
invariably stained with CD68, CD163 in tissues (Figures 1–4).
Previously, we and others showed that, in addition to CD68,
CD163, tissue granuloma MAs may express CD14, CD11c
and HLA-DR, which reflect that these activated cells in
part exhibit both MA and DC phenotypes.38–42
Based on the demonstrated cases, except for the advanced
tuberculosis, one can conclude so far that CPM is con-
sistently expressed in granuloma MAs, regardless of immune
or non-immune nature and tissue type. Therefore, CPM
appears to be a useful single IHC marker for the recognition
of any granuloma. As CPM was found to be absent in other
MA types including the resting and reactive cells, CPM
expression in EPCs should be an induced phenomenon when
EPCs are formed, as an acquired feature. Consequently, CPM
is not present constitutively in any tissue MAs, but it is
induced in distinct epithelioid–MA subpopulation(s), likely
to serve enzymatic function(s) during the course of granu-
lomatous inflammation.
MA-CPM-Protein and -mRNA Inductions with
MA-Activating Agents
The above morphological findings on human tissues with
granulomatous inflammations prompted us to check whether
IFNg could be the proximate CPM inducer in such lesions.
This is not unreasonable to assume because IFNg of the TH1
T cells is known to account for the classical MA activation
to become ‘transformed’ into EPCs in immune-mediated
granulomatous lesions.1,2,25 Therefore, we activated in vitro
normal human Mo-derived MAs with IFNg, and IL-4
(classical and alternative MA activation pathways) or CSFs.
Furthermore, as fully developed tuberculosis showed a
strikingly decreased CPM expression of EPCs (Figure 1c), an
additional MA group was included where cells were infected
with TB. The treated cells of different groups were then
collected for sectioning and IF staining, or used for syn-
chronous qRT-PCR analyses to measure CPM-mRNA levels.
Earlier, we and others demonstrated that during culturing of
Mos in the presence of 10% FBS, cells spontaneously differ-
entiated into MAs, while cytokine treatments may activate
MAs or differentiate into DCs.30,32,33,36 As shown in the
Figure 3 Lymph node (LN) granulomatous lesions also express carboxypeptidase-M (CPM). (a1–a3) Serial cryosections from fresh native LN sarcoidosis (a1)
were used for in situ laser microdissection of epithelioid cells (EPCs) from rest of the inflammatory cells (holes in a2 represent the arrow-indicated EPC
clusters of a1 after removal). The EPCs (n¼ 3) were than collected and analyzed for CPM-mRNA in the function of reference markers using quantitative
real-time reverse transcription-polymerase chain reaction (qRT-PCR) analyses (a3). Normalized to cyclophilin, CPM transcript is found the most prominent in
EPCs compared with CD86, MRC1, and PPARg macrophage and dendritic cell markers. Inset shows the positive immune-staining for CPM-protein in EPCs
obtained from the same specimen. (b and c) Granulomatous lymphadenitis exhibiting positive staining for CPM in EPCs. Note that cat-scratch disease
(b) shows suppurative necrosis (black asterisk), and arrows point to palisade EPCs with CPM positivities (light purple cells). In toxoplasmosis (c), CPMþ
EPCs are obvious (purple cells). (d) As shown in tumor-associated reactive lymphadenitis, epithelioid cells selectively express CPM, as opposed to
CD68 labeling. Note that the small framed regions representing the same microscopic field shows more prominent CPM staining compared with CD68
image (lower right, digitally magnified).
CPM in granulomas and foam macrophages
I Tsakiris et al
350 Laboratory Investigation | Volume 92 March 2012 | www.laboratoryinvestigation.org
IF photographs (Figure 5), Mos do not express CPM-protein
in detectable amounts; however, during the early phase of
Mo–MA transition, without any activating agents, cells start
producing CPM at protein levels that culminate in detectable
amounts by 12–72 h of culture (Figure 5c and d). This indi-
cates that an induced CPM-protein upregulation occurs
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during Mo–MA differentiation, in concert with previous
publication,17,18 and the levels remain elevated through-
out the culture time. As judged under the fluorescence
microscope, the CPM-protein expression levels appeared to
be increased in the presence of IFNg and IL-4 (Figure 5e and
f), but the corresponding CPM-mRNA levels did not show
Figure 4 Non-immune-mediated granuloma cells also express carboxypeptidase-M (CPM). (a and b) Besides epithelioid macrophages, foreign body giant
cells (arrows) of lung amyliodoma (a) and surgical suture-associated multinucleate macrophages (b) show CPM expression (purple cells). (c) Palisade
epithelioid cells (EPCs) of granulomatous necrotizing (N) panniculitis always express CPM. Arrows indicate positively labeled epithelioid cells (purple).
(d) As shown in the present intestinal biopsy specimen harboring Crohn’s disease, CPM-immunohistochemistry (IHC) readily and reliably ‘picks up’ the
lesional granuloma macrophage clusters (arrows, brown cells) from the rest of CD163þ non-granulomatous macrophages.
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significant further increase in IFNg-treated MAs as compared
to non-treated cells (Figure 5g). However, M-CSF and
IL-4þGM-CSF (leading to DC differentiation) could induce
significant CPM-mRNA transcripts at 48 h (Figure 5h), but
the increase returned to a nonsignificant value for M-CSF by
the end of culture time (not shown). Figure 6a demonstrates
Figure 5 In vitro carboxypeptidase-M (CPM) expression during monocyte–macrophage (Mo–MA) differentiation and in response to activating cytokines.
(a–f) CPM-immunofluorescence (IF) of paraffin-embedded sections obtained from cell cultures during Mo–MA differentiation in the presence or absence
of activating cytokines. As demonstrated, monocytes do not express CPM. Differentiating macrophages, however, start expressing CPM, which is
culminated at 12th hour (c, red fluorescence) and remains elevated during the culture time (d). Although, interleukin-4 (IL-4) and interferon-g (INFg)
apparently increases the CPM-protein expression levels (e and f), the corresponding CPM-mRNA (n¼ 3), normalized to cyclophilin, showed no
significant upregulation in Mo-derived MAs during the 72-h stimuli (g). In contrast, separate experiments showed that CPM transcripts of macrophages
are significantly increased at the 48th hour of culture time in the presence of macrophage-colony-stimulating factor (M-CSF) and IL-4þgranulocyte–
macrophage-colony-stimulating factor (GM-CSF) (*), the latter representing cells under maturation toward dendritic cells (h). Original magnifications
for IF images:  40; the nuclear counterstain is 40-6-diamidino-2-phenylindole (DAPI) (blue fluorescence).
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the timescale for CPM-mRNA levels, comparable to IF
findings. Remarkably, there was a significant increase in
CPM-mRNA at the 12th-hour time point of culture in
differentiating MAs compared with Mo-mRNA levels
(Figure 6a, light gray columns), indicating a rapid synthesis
of CPM during Mo–MA transition. In addition, this figure
draws attention to an interesting phenomenon, indicated
earlier by the IHC (Figure 1c): the presence of TB markedly
and gradually downregulates CPM-mRNA of infected MAs
(Figure 6a, dark gray columns). By the 72nd hour of culture
and in the presence of bacilli, basically no CPM transcript
was found in infected MAs and the inhibition of CPM-
mRNA proved to be significant compared with non-infected
cells at each time point, even though that 25% of the infected
cells died out by the end of the experiment. The IF findings
demonstrated the same phenomenon at protein levels, as
CPM-peptide nearly disappeared by the 48th hour of culture
time (Figure 6c), while the TB-free (control) MAs preserved
the normal upregulated CPM expression level (Figure 6b).
When, however, heat-inactivated killed bacilli were used
(HK-TB), only mild decreases in CPM transcript and
protein levels occurred (Figure 6d), indicating that only
live mycobacteria are capable of downregulating MA-CPM
significantly. On the other hand, live TB-infected MAs up-
regulate CD14 and CD11c, but not HLA-DR (Supplementary
Figure S3), consistent with previous publications.21,39,40
TGF-b, which is known to be regulated in DCs,41 did not
change the CPM expression pattern of both differentiating
MAs and DCs and no alteration was found in HLA-DR
expression (Supplementary Figure S4).
CPM Expression in Lipid-Laden Tissue MAs
During the tissue screening for CPM-protein using IHC, we
found that lipid-laden MAs also consistently express fair
amounts of CPM-protein that can be detected as easily as in
granuloma-EPCs. Remarkably, foam MAs of gallbladder
cholesterolosis, early atherosclerotic plaques and xanthoma-
tous lesions always express CPM (Figure 7a– c), unless these
cells became senescent or degenerated (not shown). More-
over, a robust CPM expression is seen in MAs of
type-I Gaucher’s disease (Figure 8a), a genetic defect of
cerebrosidase.43 This enzyme deficiency results in excess
amounts of unprocessed glycolipids in phagocytes that
become lipid-laden ‘Gaucher’s cells’ and accumulate in
lymphoid tissues and spleen.44 Similarly to this finding,
intense CPM expression is recognized in lipid pneumonias
Figure 6 Live but not dead mycobacteria downregulate carboxypeptidase-M (CPM) transcript and protein in macrophages (MAs). (a) mRNA levels
of CPM during in vitro differentiation of monocytes into MAs are shown in the presence of interferon-g (IFNg) or Mycobacterium bovis-bacillus Calmette–
Gue´rin (BCG) tuberculosis bacilli (TB) at various time points. As shown, control samples at 12 h vs 0 time point and TB-treated vs control (non-infected)
samples at all the indicated time points were found significant. (b and c) The immunofluorescence (IF)-stained macrophages revealed striking
downregulation in CPM-protein expression by the 48th hour of culture when infected with TB (c) compared to control (non-infected) macrophages
expressing CPM (b, red fluorescence). (d) In separate experiments (n¼ 3), cells were harvested at 24 h after treatment with live (L) or heat-killed (HK)
TB bacilli followed by a reverse transcription-polymerase chain reaction (RT-PCR) analysis for CPM-RNA expression. As shown in this figure, significant
CPM-mRNA downregulation occurred only in MAs that were infected with live TB, but no remarkable decrease in transcript was found when HK bacilli
were used, suggesting that CPM downregulation is likely dependent on the viability of mycobacterium. All PCR data shown in panel a and panel d are
expressed as a ratio of the CPM transcript relative to cyclophilin expression. Error bars indicate the s.d. of the relative expression. *Significant (Po0.05)
compared with the respective control value.
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Figure 7 Cholesterol-laden tissue macrophages always express carboxypeptidase-M (CPM). (a–c) CPM expressions by xanthomatous tissue
macrophages (arrows) are demonstrated in various lesions, including cholesterolosis (a) and gastric mucosa xanthoma (c). As shown in the serial
sections of an early atherosclerotic plaque (b), foam macrophages are distinctly labeled by CPM, comparable with CD68 pattern (arrows).
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(Figure 8b) and tumor-associated MAs when related to
tissue damage, and in turn lipid uptake takes place (Figure 8c
and d). Lipid granulomas always show CPM positivity
(not shown).
Serum- and Lipid-Supplemented MAs have Enhanced
CPM Expression
The CPM-IHC results on lipid-laden tissue MAs guided us
to perform additional in vitro experiments. Following a
Figure 8 Carboxypeptidase-M (CPM)þ foam cell accumulation in various pathological disorders. (a) Type-1 Gaucher disease, a genetic defect of
cerebrosidase results in a lipid-laden macrophage accumulation, which expresses remarkably large amounts of CPM-protein, probably in association with
glycolipid uptake. (b) Lipid pneumonia is characterized by the accumulation of foam macrophages, which constantly express CPM along the cell membrane
(cells with purple cytoplasmic membrane). (c and d) Tumor-associated macrophages (TAM) express CPM when related to significant cell destruction, and in
turn lipid uptake occurs by the phagocytes. Arrows in images c exhibiting breast cancer point to live neoplastic cell nests surrounded by CPMþ
macrophages (MAs). (d) The same microscopic filed of classic testicular seminoma obtained from serial sections (v indications are for the same vessel): note
that epithelioid TAMs (long arrows) are strongly positive for CPM; as opposed, CD68 also labels other macrophage types with no epithelioid cell (EPC)
morphology (short arrows).
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transient 4-h culture of cells in 2% FBS to allow adherence,
Mo-derived early MAs were then further maintained in
FBS-deprived culture medium (0.5% FBS) or they were
cultured in medium containing 10% FBS (control MAs),
or supplemented with oxLDL, LDL or VLDL. As shown
Figure 9a, CPM-mRNA expression of LDL-supplemented
MAs exhibited an enhanced upregulation as compared with
values of cells kept in 10% FBS alone. Not surprisingly, the
CPM-protein was found also upregulated in differentiating
MAs in the presence of 10% FBS (control MAs; Figure 9c)
while displaying cytoplasmic lipid droplets, as opposed to
low CPM-protein expression level of MAs, which were kept
in 0.5% FBS (Figure 9b). Furthermore, MAs in CCSS,
representing lipid-depleted condition, express decreased
CPM, while adding LDL to CCSS the lipid alone enhanced
the CPM transcript expression levels (Figure 9d). HDL
and oxLDL did not affect CPM expression pattern, but
VLDL could enhance CPM, comparable with LDL (not
shown). The combined mRNA and protein data, therefore,
serve as in vitro evidence that LDL is one of the lipids that
prominently orchestrates the upstream CPM regulation
during the early phases of MA differentiation. Based on flow
cytometry analysis, neither CCSS nor LDL altered CD14 and
CD11c expression patterns on differentiating MAs (Supple-
mentary Figure S5). In further support of the lipid-signaling
pathway, when PPARg (a lipid-regulated nuclear receptor)
of DCs was induced using a potent PPARg-activating agent
RSG to decrease intracytoplasmic lipids (as demon-
strated earlier by us and others45,46), the CPM-protein level
became remarkably decreased in these cells, as judged by
comparative immunoperoxidase labeling (Supplementary
Figure S6).
Figure 9 Carboxypeptidase-M (CPM) upregulation is mediated by lipids including low-density lipoprotein (LDL). (a) mRNA levels of CPM in differentiating
macrophages (MAs) after 24-h treatments with LDL or oxidized LDL (oxLDL). Data (n¼ 3) are plotted as ratios of the transcripts relative to cyclophilin
expression. Error bars indicate the s.d. of the relative expression. *Po0.03, compared with the respective control value of cells kept in 10% fetal bovine
serum (FBS), only. As shown, supplementation of 10% FBS with LDL, but not oxLDL, resulted in a significant CPM upregulation. (b–c) IF-stained MAs show no
upregulation in CPM-protein expression when serum-depleted (0.5% FBS) culture medium is used (b), as opposed to normal elevated CPM level in cells
(red fluorescence) kept in 10% FBS-containing medium (c). (d) In separate experiments (n¼ 3) using cells obtained from other donors, MAs were maintained
in either 1% FBS or charcoal-stripped serum (CCSS) for 24 h, instead of 10% FBS (control). As indicated in this figure, the CPM transcript remained
significantly downrepresented (*Po0.05) in both cases; however, when CCSS was supplemented with 20 mg/ml LDL, the CPM upregulation return to high
levels, comparable with differentiating control cells kept in 10% FBS. Original magnification for immunofluorescence (IF) images with 40-6-diamidino-2-
phenylindole (DAPI) nuclear counterstain (blue):  40.
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GM-CSF-Mediated CPM Gene Activation during Early DC
Differentiation
When MAs were maintained in 10% FBS for 12 h followed
by a 5-day culture in the presence of IL-4þGM-CSF to induce
DC differentiation, there was a remarkable increase in
CPM-mRNA and concomitant protein upregulations. The
corresponding microarray data show that following an acute
CPM-gene upregulation during Mo–MA differentiation,
primarily associated with lipid uptake from FBS (Figure 10a
and c), there is a further increase in CPM gene activation
during the early MA–DC transformation; the latter is mediated
by the cytokines IL-4þGM-CSF (Figure 10b). Importantly,
during the early DC differentiation, the immature cells, dis-
playing antigen-presenting morphology, still harbor cyto-
plasmic lipid, although the quantity appears to be lower
compared with early MA-lipid contents at 12 h (Figure 10c
versus d). On the other hand, CPM-protein remained elevated
in DCs by the end of culture time (Figure 10e). By using a
combined novel in situ IF staining on monolayers for the
simultaneous detection of CPM (visualized with FITC) and
lipids (applying the red fluorescent Nile-red), it is obvious that
the two cellular components are indeed co-present synchro-
nously in DCs (Figure 10f).
DISCUSSION
The phenotypically and functionally versatile MAs are major
participants in inflammations, lipid metabolism, immunity
and tissue remodeling via phagocytic, antigen-presenting and
cytokine-producing capacities.47,48 This study has generated
compelling evidence for the first time that by using a single
CPM-IHC, the morphologically distinct MA subpopulations,
the EPCs of granulomatous inflammations and the foam cells
can be selectively identified with high specificity and accep-
table sensitivity from the rest of tissue MAs in paraffin
sections. Therefore, CPM appears to be a reliable marker
when there is a need to confirm the presence of minute
granuloma in a biopsy specimen or in tissues not unambi-
guous for granulomatous or xanthomatous lesions. This is
based on the consistent IHC finding that CPM in resting
MAs is not present constitutively at detectable amounts;
instead, CPM-protein expression is induced exclusively in
EPCs along with the transcript as confirmed by qRT-PCR
analyses of the microdissected tissue granuloma MAs.
In vitro, CPM upregulation could be reproduced under
two conditions: (i) in association with lipid environment
during Mo–MA differentiation, and (ii) in response to
M-CSF and IL-4þGM-CSF, resulting in DC transformation.
Both the fatty-changed EPCs and the CSF microenvironment
have been described in granuloma MAs,21,26,34 providing a
rational explanation for the consistent CPM positivities on
tissue sections. Despite the selective expression of CPM in
granuloma EPCs, indicating IFNg effect,1 the present in vitro
experiments ruled out a dominant role of either IFNg or IL-4
alone (common MA activators) as possible upstream CPM
regulators at transcriptional levels. On the other hand, the
observed CSF-induced CPM expression reflects previous data
that CPM of bone marrow’s mononuclear hematopoietic cells
is upregulated in the presence of CSF.49
The interesting finding that live but not dead mycobacteria
downregulate CPM in infected MAs is likely to be associated
with the intracellular virulence of the organism. The mole-
cular mechanism of mycobacteria-mediated CPM inhibition
is unclear yet and this issue was beyond the scope of this
study, but will warrant further research. Nevertheless, we
earlier documented that live mycobacteria can activate
PPARg to decrease the intracytoplasmic lipid droplets of
infected MAs,34 and as demonstrated in this study, RSG-
activated PPARg upregulation of DCs, resulting in lipid
efflux, comes with a substantially decreased MA-CPM-pro-
tein expression (Supplementary Figure S6), an observation
that may serve as a preliminary and hypothetical explanation.
The in vitro lipid-induced upstream CPM expression,
which could be further enhanced with LDL or VLDL, corre-
lates with the IHC finding that foam MAs do consistently
exhibit CPM at tissue levels. The present observation
confirms previous results, which demonstrated that CPM is
an MA-differentiation marker,16–18 but the CPM upstream
expression is primarily associated with lipid uptake by MAs
during maturation. On the other hand, our microarray re-
sults have shown that during MA–DC transition, a robust
upstream CPM expression develops at both transcriptional
and protein levels, while cells keep exhibiting cytoplasmic
lipids. As opposed, when the lipid-regulated transcription
factor PPARg of DCs was activated by RSG to decrease
intracytoplasmic lipids,46 the CPM-protein expression
became downregulated. Taken together, these phenomena are
consistent with the recent GeneChip-based genome-wide
expression microarray data, which demonstrated that during
the transition of MAs into DCs, the acutely upregulated
genes were associated with lipid metabolism, which in turn
may modify and activate genes primarily involved in immune
functions.33 These data correlate with the recent publication
that resident intimal DCs accumulate lipids and contribute to
the initiation of atherosclerosis,50 that is, foam cells in
plaque, which we have now revealed to be positive for CPM
(Figure 7b). These data and the present IHC findings
on tissues all make it reasonable to speculate that in certain
tissue microenvironments, notably necrosis, lipid-rich
atheromatous plaques of arteries with inflammatory MAs
actively upregulate CPM; this is possibly for an enzymatic
action on proinflammatory peptide(s) involved in cell sig-
naling for lipid metabolism51,52 to scavenge unwanted lipids
at tissue sites, which in turn causes the effector MAs to
become transformed into foam cells. Consistent with this
concept, the AEBP1, a transcriptional nuclear repressor with
carboxypeptidase activity, has recently been shown to be
able to suppress macrophage–cholesterol efflux, via PPARg1
and LXRa downregulations, thereby promoting foam cell
formation.9 However, we could rarely detect AEBP1 protein
in foam MAs of human paraffin tissue sections using IHC
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techniques (unpublished data). Nevertheless, based on the
cited reference and our present data, the simultaneous pre-
sence of the cell membrane-bound CPM and the nuclear
AEBP1 carboxypeptidases appear to have active roles in
macrophage lipid regulation, probably via processing pep-
tide(s) that directly or indirectly govern both the lipid
Figure 10 Microarray data for CPM gene activation during monocyte-macrophage (MA) and MA-dendritic cell (DC) differentiations associated with serum
lipids and cytokines. (a and b) Microarray analyses using various probe sets (identified by numbers with different color lines on graphs) show that during
monocyte to MA differentiation, there is a robust acute CPM gene activation (a), which is increased further during monocyte-derived MA transition into early
DCs induced by interleukin-4þ granulocyte–macrophage-colony-stimulating factor (IL-4þGM-CSF) (b). (c and d) The lipid (Oil-Red-O) staining of these
monolayer cells, viewed under partial phase-contrast lights, revealed remarkable lipid uptake by differentiating MAs (thick arrows of c), which appears to be
correlated with CPM-gene upregulation. (d) At 48 h of culture with GM-CSFþ IL-4, monocyte-derived differentiating cells having cytoplasmic projections
(arrows), a typical dendritic cell morphology, still contain cytoplasmic lipids (thick arrow), albeit in lower quantity compared with cells of image c.
(e) The section of paraffin-embedded cell pellets shows that at the end of differentiation time, CPM-protein expression remains elevated in immature
DCs (red fluorescence), which reflects the gene-activating effects of the cytokines applied. (f) The combined fluorescent staining for CPM (green) and
Nile-red for neutral lipids (red) simultaneously shows that the lipid content of DCs did not disappear completely by the end of the 5-day culturing time,
while CPM-protein is still being expressed, consistent with the gene-expression profile of Figure 10b. (g) Monocytes contain neither lipid nor CPM, as
expected. Images of (c and d) and (f, g) are from monolayer cells with  63 original magnifications. Nuclear counterstaining: methyl-green for panels
c and d and 40-6-diamidino-2-phenylindole (DAPI) (blue fluorescence) for panels e, f and g.
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uptake/influx facilitation (a CPM effect) and the lipid efflux
inhibition (an AEBP1 effect), all promoting foam cell for-
mation. In fact, the novel immunohistochemical observation
of the selective and inducible expression of CPM-protein in
certain macrophages at natural tissue environments reflects
functionally distinct subpopulations that are readily detect-
able with CPM-IHC for diagnostic purposes. On the other
hand, the present uncovered lipid metabolism-related fea-
tures of CPM in differentiating MAs and DCs, which were
not previously described, may serve as a new potent pro-
atherogenic-inducible cellular molecule of MAs, which is
upregulated by distinct environmental pro-inflammatory
cytokines and lipids, but downregulated in mycobacterium-
infected cells and can potentially be targeted. These issues
merit further investigation.
Supplementary Information accompanies the paper on the Laboratory
Investigation website (http://www.laboratoryinvestigation.org)
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